SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironments fiscal first-quarter results beat expectations, with record funded backlog and strong bookings drawing renewed interest in its drone and counter-drone business. Traders are divided: some view the results and laser-system contracts as evidence of demand, while others question the muted outlook, profitability and valuation, contributing to choppy price action.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Rev8 lidar partnership with Seneca for autonomous wildfire-response drones is drawing attention as another potential commercial use for its sensing technology. Traders are optimistic about broader adoption across robotics and autonomy, but debate the stocks sharp swings and whether deployments can translate into sustained growth.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are using SQQQ as a hedge or speculative bet on a Nasdaq pullback, citing concerns that AI and tech valuations are overheated and the rally is vulnerable despite record highs. Others warn that the Nasdaqs strength and SQQQs leveraged daily-reset decay make holding the inverse ETF risky.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Oppenheimers upgrade to Outperform, citing rising contract values and early monetization of agentic AI traffic, is driving attention to Fastly. Bulls view the AI and edge-cloud opportunity as a growth catalyst, while skeptics question whether the upgrade justifies the rally and some traders speculate about short covering.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are rebounding after a sharp selloff triggered by CEO CJ Desais abrupt departure for Meta. Traders cite former CEO Dev Ittycherias return as interim chief, upbeat Investor Day guidance and an expanded stock-buyback authorization as support, while some remain concerned about leadership succession and volatile trading.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Anticipation of Sareptas upcoming DM1 and FSHD clinical data is driving attention amid a sharp, high-volume rebound. Traders are debating whether the move reflects short covering or an undisclosed catalyst, while buyout and news-leak speculation remains unconfirmed.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscalers Investor Day, reaffirmed guidance, and long-term ARR ambitionsalongside an IBM and Red Hat security collaborationare driving attention, with multiple analysts raising price targets. Traders are broadly encouraged by the AI-security opportunity, though some question whether the companys growth ambitions justify its valuation.

WISeKey International Holding Ltd. is a cybersecurity company, which engages in offering digital security technology solutions. The firm operates through the Internet of Things (IoT), and Managed Public Key Infrastructure (mPKI) segments. The IoT segment refers to the design, manufacturing, sales and distribution of microprocessors operations. The mPKI segment includes all operations relating to the provision of secured access keys, authentication, signing software, certificates and digital security applications. The company was founded by Joao Carlos Creus Moreira and Philippe Doubre in 1999 and is headquartered in Zug, Switzerland.

WISeQey Corp.

WQEYs sharp decline is being discussed alongside its reverse split/share conversion and ticker transition, which have left some traders confused about their holdings and trading-platform updates. The community is also debating whether its stakes in WISeSat and the newly announced Quantisimo combination are undervalued assets or obscured by a complex corporate structure and dilution concerns.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios addition to the S&P 500 is drawing attention, with traders pointing to expected index-fund buying and unusually heavy volume; some attribute the moves volatility to rebalance-related flows and profit-taking. The broader debate weighs optimism that AI agents will lift communications demand against concerns about valuation, competition, and how much of that growth Twilio can monetize.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas strong weekly rally has traders focused on expanding Cybercab registrations in Texas and rising Shanghai exports, while some also cite an upcoming Roadster event. The move has prompted bullish talk of a squeeze, but others view it as overextended and expect a pullback amid volatile options trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences Citius Pharmaceuticals to Participate in September 2026 Investor Conferences PR Newswire CRANFORD, N.J., Sept. 3, 2026 Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 Million in revenue for the first...

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., Aug. 14, 2026 $7.1 million in revenue for the first nine months...

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri PR Newswire CRANFORD, N.J., Aug. 12, 2026 CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology...

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment PR Newswire CRANFORD, N.J., Aug. 5, 2026 New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal...

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Citius Oncology Inc.

Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.8398
Prev Close	$0.835
Open	$0.842
Dividend Yield	0.00%
50-Day Moving Average	$0.8569
Beta	-2.06
Avg. Volume	104,313.10
PE Ratio	-1.77

52-Week High	$2.25
52-Week Low	$0.4912
Market Capitalization	$77.64M
EPS (Annual)	-$0.338
Price to Book	2.20
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

CTOR Fundamentals